In conclusion, dual targeting of the Aurora A kinase and mTOR resulted in marginal clinical benefit in a population of patients with refractory solid tumors, including a cohort of patients with pancreatic adenocarcinoma. The gene discussed is AURKA; the disease is pancreatic adenocarcinoma.